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Human Papillomavirus (HPV) vaccine has been shown to prevent cervical cancer. 
Numerous studies have examined factors associated with HPV vaccine series initiation, but little 
is known about factors associated with age of initiation of HPV vaccine. Using cross-sectional 
data from the 2011 National Immunization Survey-Teen, this study examined the relationship 
between Advisory Committee on Immunization Practices’ recommended age at initiation of the 
HPV vaccine series and socioeconomic status, race/ethnicity, and health insurance among 13-17 
year-old females who received at least one HPV vaccine shot (n=5,965). On-time initiation of 
HPV vaccine series was significantly associated with having public health insurance (AOR: 
1.825, 95% CI: 1.266, 2.631). Females with college-graduated mothers (AOR: 0.669, 95% CI: 
0.487, 0.918) or household income greater than $75,000 (AOR: 0.746, 95% CI: 0.568, 0.98) 
were less likely to initiate on-time. Research is needed to further investigate the reasons for late 
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CHAPTER 1: INTRODUCTION 
 
Human Papillomavirus (HPV) is one of the most common sexually transmitted diseases 
in the United States (U.S.) and worldwide (1). Approximately 20 million people are currently 
infected with HPV in the U.S. and about six million more are infected each year (2). About half 
of these infections are among 15-24 year-old young adults (2). More than half of sexually active 
men and women are infected with HPV at some time in their lives (2).  
Furthermore, being infected with HPV is the greatest risk factor for cervical cancer (3). 
According to the World Health Organization (WHO), cervical cancer is the third most common 
type of cancer among women worldwide (4). Centers for Disease Control and Prevention (CDC) 
estimates that the U.S. spends more than $4 billion in direct health care costs for treatment of 
HPV-related diseases each year (1). Other studies estimate that the cost per quality-adjusted life 
year (QALY) gained by HPV vaccination of 12 year-old females ranges from $3,000 to $43,600 
per person (1, 5, 6). With rising healthcare expenditures in the U.S., using HPV vaccination as a 
preventive health measure offers our nation an enormous cost-saving opportunity. 
Advisory Committee on Immunization Practices (ACIP) Recommendations for HPV 
vaccination 
 
The U.S. Food and Drug Administration (FDA) approved two HPV vaccines, “Gardasil” 
in 2006 and “Cervarix” in 2009, to protect against high-risk HPV types (HPV-6, HPV -11, HPV-
16, and HPV-18) which caused approximately 70% of occurrences of cervical cancer in the U.S. 
(2, 7, 8). As a result, the CDC’s Advisory Committee on Immunization Practices (ACIP) 
recommended the routine use of HPV vaccination among 9-26 year old females and males. The 
ACIP recommendation for female use of HPV vaccination was released in 2007 with an 




(9). All recommendations were based on series of clinical trials, where HPV vaccines were 
proven to be safe and effective for these age groups. 
The ACIP recommended that the first HPV shot of a three-dose vaccine series be initiated 
by 11 or 12 years of age (1, 10, 11, 12). Each 0.5 milliliter-dose should be administered over a 
six-month period: the second dose is to be 1-2 months after the first dose and the third dose is to 
be given 6 months after the first dose (10, 11). It is highly recommended that children initiate 
HPV vaccination before they become sexually active and contract HPV infections (10, 11). 
Delaying initiation of the HPV vaccine series decreases protection against the HPV infection and 
can lead to the development of cervical cancer and serious HPV-related diseases in adulthood 
(9). Despite these recommendations, CDC estimates that only 30% of U.S. females received 
three doses of the HPV vaccine by ages 13-15 in 2011 (13, 14).  
HPV vaccination is most effective if initiated prior to exposure to HPV infection (10, 12). 
Data from the 2003 National Survey of Adolescents and Young Adults suggests that there is low 
opportunity for HPV exposure at 11 years of age or younger since sexual experience is still very 
low (52). By the age 14, there is a significant increase in opportunity for HPV infection exposure 
(52). Therefore, compliance with ACIP recommendations for age at initiation of HPV vaccine 
series is extremely beneficial.  
Research has shown that HPV vaccine does not treat infection for people who have 
already been infected with HPV (72). Although some people may already have acquired one or 
more type of HPV infection, HPV vaccine could still protect them from other types of HPV 






Importance of Timing of the HPV vaccine series 
 Timing of initiation of the HPV vaccine series may be more essential than completing all 
three HPV vaccine doses, according to previous randomized controlled studies (69, 70). Study 
findings confirmed that earlier initiation of HPV vaccination for females were more effective 
compared to later initiation of HPV vaccination (68). Furthermore, they found that females who 
received two doses of HPV vaccination gained a similar protective effect as those who received 
three doses (68, 69, 70). The risk for HPV infection decreased tremendously after receiving only 
two doses of HPV vaccination (69, 70). Compared to females with no vaccination, females who 
received two doses of HPV vaccination had 0.29 (95% CI, 0.21, 0.40) odds for the HPV 
infection risk, whereas females who received all three doses of HPV vaccination had 0.18 (96% 
CI: 0.15, 0.22) odds for the HPV infection risk (69). 
Racial/ethnic disparities in the HPV vaccine series initiation in the United States 
In the U.S., the number of cervical cancer cases and deaths significantly decreased over 
the past several years (15). This decrease is thought to be due to the success of public health 
preventions and wide-scale implementation of Pap smear screenings (15). Despite this reduction, 
non-Hispanic Blacks and Hispanics are less likely than non-Hispanic Whites to initiate the HPV 
vaccination series (18, 19, 20, 21). 
Disparities in the utilization of preventive services exist between whites and racial/ethnic 
minorities (75, 76, 77). Compared to Whites, Hispanics, Asians, and Blacks are less likely to use 
preventive services, including cervical cancer screening (75, 76, 77). Additionally, racial/ethnic 
minorities are less likely than whites to have health insurance, as were people with low SES 






CHAPTER 2: RESEARCH QUESTIONS AND HYPOTHESES 
 
The overall goal of this thesis was to assess compliance with ACIP recommendation 
regarding age at initiation of the HPV vaccine series, and identify related socioeconomic status 
(SES), racial/ethnic, and health insurance coverage factors. This study aimed to: 
1) Compare age at initiation of HPV vaccine series with ACIP recommendations among 13-
17 year-old females who received at least one dose of the HPV vaccine series. 
2) Examine variations in compliance with ACIP recommendations for age at initiation of the 
HPV vaccine series by SES, race/ethnicity, and health insurance coverage. The 
association was assessed by the following questions: 
a. Was initiating the HPV vaccine series at the ACIP-recommended age associated 
with SES? 
 
H0: SES was not associated with timely initiation of the HPV vaccine series. 
People with higher SES were as likely to report having received their first HPV 
shot on-time as people with lower SES. 
 
H1: SES was associated with timely initiation of the HPV vaccine series. People 
with higher SES were more likely to report having received their first HPV shot 
on-time compared to people with lower SES. 
 
b. Was initiating the HPV vaccine series at the ACIP-recommended age associated 
with race/ethnicity? 
 
H0: Race/ethnicity was not associated with timely initiation of the HPV vaccine 
series. Racial/ethnic minorities were as likely to report having received their first 
HPV shot on-time as non-Hispanic Whites. 
 
H1: Race/ethnicity was associated with timely initiation of the HPV vaccine 
series. Racial/ethnic minorities were less likely to report having received their 





c. Was initiating the HPV vaccine series at the ACIP-recommended age associated 
with having health insurance coverage?  
 
H0: Having health insurance coverage was not associated with timely initiation of 
the HPV vaccine series. 
H1: Having health insurance coverage was associated with timely initiation of the 
HPV vaccine series. 
 
The study population for the 2011 NIS-Teen survey was 13 - 17 year-old children at the 
time of the interview in 2011. Since the ACIP recommendation for male use of the HPV vaccine 
did not appear until the end of 2011, we excluded all males as well as any out of range ages from 
the analysis. This study's inclusion and exclusion criteria, data source, and sample size (n= 






























CHAPTER 3: BACKGROUND: REVIEW OF LITERATURE 
 
Factors associated with HPV vaccine uptake in the United States 
In addition to race/ethnicity and SES, infrequent healthcare visits and lack of health 
insurance coverage have been frequently cited as barriers to receiving timely vaccinations (16, 
17, 20, 22, 24, 54, 66). The HPV vaccine is one of the most expensive vaccines with an 
estimated cost of $390 total ($130 per dose) to administer three HPV vaccine shots over a six-
month period (54, 66). In the U.S., private health insurance covered the cost of vaccinations for 
many individuals. Public health insurance, such as Medicaid and the Vaccines for Children 
Program (VFC), covered vaccinations for low-income individuals (54). Individuals without 
health insurance coverage were the most likely to face the high cost of vaccination. This may be 
their greatest barrier to receiving HPV vaccination (54). The implementation of the Patient 
Protection and Affordable Care Act (ACA) is expected to decrease the number of uninsured 
individuals and consequently lead to an increase in HPV vaccine uptake (25). 
A systematic review of 25 published peer-reviewed studies on “factors associated with 
HPV vaccine uptake in teenage girls” found that higher HPV vaccine series initiation was 
associated with socioeconomic status, race/ethnicity, and health insurance coverage (20). Having 
some type of health insurance coverage, whether private or public, was associated with higher 
HPV vaccine series rates compared to not having health insurance coverage. Interestingly, the 
HPV vaccine series initiation rate was highest among people with public health insurance, 
compared to those with private health insurance. Other factors associated with HPV vaccine 





In 2013, Fisher supported some of Kessels’ findings with a more comprehensive 
systematic review and meta-analysis of the literature regarding racial/ethnic and SES differences 
in HPV vaccine uptake (21). Incorporating more recent published articles, Fisher’s updated 
review strengthened some of Kessels’ findings on disparities in HPV vaccine initiation 
experienced by racial/ethnic minorities and people without health insurance coverage (21). 
Interestingly, Fisher did not find a significant association for HPV vaccine initiation and 
mother’s education and income (21).  
National pattern for HPV vaccine and other childhood vaccines in the U.S. 
 In general, the same patterns are found for uptake of childhood vaccines with the 
exception of HPV (74). In the U.S., vaccination coverage was comparable for Tdap, 
MenACWY, MMR, hepatitis B, and varicella across poverty levels and racial/ethnic groups. 
Coverage for all of these vaccines was lower for those with low SES as well as those who are 
racial/ethnic minorities (74). However, HPV vaccination coverage did not follow this pattern. 
Higher HPV vaccination coverage was observed for people living below poverty level (74). Both 
Hispanic males and females had higher initiation rates for HPV vaccine while HPV vaccine 
series completion was lower among Hispanics and blacks, compared to whites (74). 
Efforts to increase HPV vaccine uptake in the United States 
Public programs exist to offer assistance to individuals who do not have health insurance, 
based on specific eligibility criteria. These programs include the Vaccines for Children Program 
(VFC), Immunization Grant Program (Section 317), Medicaid, Children’s Health Insurance 
Program (CHIP), and Patient Protection and Affordable Care Act (ACA) (26, 27, 28, 29).  
Vaccines for Children Program (VFC). This program covers vaccines recommended by 




those who are categorized as “underinsured” (27, 30, 31, 32). Underinsured children are defined 
as children who have private health insurance that does not cover vaccination (27, 31, 32).  Free 
vaccines are also offered to children who are Medicaid-eligible and have American Indian or 
Alaskan Native background (27, 31, 32). Because the VFC Program supplies vaccines to all 
states, it has increased vaccine uptake among eligible children younger than 19 years old while 
lowering vaccine prices for all states (30). 
 Immunization Grant Program (Section 317). Federal grants are distributed to state and 
local government public health agencies to subsidize vaccine costs and to help cover children 
younger than 19 years old who are not eligible for the VFC program (28). This program attempts 
to close the gap for children who were not covered under VFC, but require assistance paying for 
vaccines. 
 Medicaid. Medicaid covers HPV vaccination for 19-20 year-old adolescents who are 
eligible to receive Medicaid (27).  
Children’s Health Insurance Program (CHIP). This program provides health insurance 
coverage to approximately 8 million children whose families do not qualify for Medicaid but are 
not able to afford private health insurance (33).  
Patient Protection and Affordable Care Act of 2010 (ACA). ACA requires most health 
insurance plans to provide 100% coverage for HPV vaccines without any cost-sharing to any 
enrollees starting September 23, 2010 (27, 34, 35). This means that most private health insurance 
plans are mandated to cover HPV vaccine with no co-pay or deductibles after the implementation 
of the ACA (27, 34, 35, 73). Newly eligible people for Medicaid in states that chose to expand 
coverage are also covered for the HPV vaccine series without any cost-sharing expenses (27).  




prohibition to deny coverage due to pre-existing conditions, took effect starting January 1, 2014 
(27, 34, 35, 73). The implementation of the ACA narrows the gaps in HPV vaccination funding 
and is expected to increase access to preventive services including access to the HPV vaccine in 
the U.S. While the ACA requires that most U.S. citizens and legal residents have health 
insurance coverage or pay penalty fees, some people are still left out of the health insurance 
system (37). People who are not required to have health insurance coverage include those who 
are a part of any religion opposing a health insurance plan, undocumented immigrants, in prison, 
a member of any Indian tribe, have family income below the tax return filing threshold, and 
paying more than 8% of total income for a health insurance plan (37). It is estimated that full 
implementation of the ACA still leaves about 23 million people without health insurance (38, 39, 
61, 71). Access still remains one of the most difficult challenges for these subgroups of the U.S. 
population (38, 39, 71). 
Furthermore, having health insurance coverage did not necessarily mean one has access 
to healthcare (71). According to Penchansky and Thomas, access to healthcare includes 
availability, accessibility, accommodation, affordability, and acceptability (40). Health insurance 
coverage only contributes to a portion of an individual’s overall health and well-being (71). 
Having health insurance coverage does not necessarily determine ultimate health outcomes (71).  
Gaps in the literature 
Numerous studies, such as those discussed in Kessels’ and Fisher’s systematic reviews, 
have examined factors associated with initiation of the HPV vaccination series, but little is 
known about factors associated with timely HPV vaccine uptake (20, 21). This study focuses on 
the importance of compliance with ACIP recommendation regarding age of initiation or on-time 




This study builds on prior research studies examining factors associated with initiation of 
HPV vaccine. New knowledge from this study could equip us with better knowledge on timely 
initiation of HPV vaccine series. Population-targeted interventions could be developed to address 

























CHAPTER 4: METHODS 
 
The National Immunization Survey –Teen (NIS-Teen) was used to conduct this cross-
sectional study (2011). The 2011 NIS-Teen was conducted jointly by the National Center for 
Immunizations and Respiratory Diseases (NCIRD) and the National Center for Health Statistics 
(NCHS) (41). 
The 2011 NIS –Teen Survey collected data from both households and vaccination 
providers (42). The first part of the two-phase survey was the random-digit-dialing telephone 
survey with randomly selected households in all 50 states and the District of Columbia (42). 
Participant’s consent was obtained from parents or guardians of eligible children in order to 
contact their vaccination providers. The second phase of the survey was to perform a record 
check with the vaccination providers through mail survey questionnaire (42). The purpose of 
sending the mail surveys to the vaccination providers was to collect children’s immunization 
data from their medical records and to assure the accuracy and precision of overall vaccination 
coverage estimates (42). 
In order to reduce measurement error, the 2011 NIS-Teen staff collected the children’s 
date of birth instead of directly asking for the age of the children during the first phase of the 
study (42). Various methods were used to minimize bias. Computer-assisted telephone 
interviewing (CATI) software was used to calculate children’s age and determine their eligibility 
(42). The 2011 NIS-Teen also collected dates of vaccine shots from the second phase of the 
study. Vaccination dates were used with the children’s dates of birth to calculate the age of 






The study population for the 2011 NIS-Teen was 13-17 year-old children at the time of 
the interview in the 2011 calendar year (42). Children ages 13-17 years during the 2011 data 
collection were required to have their birth year between 1993 and 1999 in order to be included 
in the survey study (42). The 2011 NIS-Teen was conducted in conjunction with the 2011 NIS. 
While the 2011 NIS obtained vaccination coverage rates among children who were between 19 
and 35 months old for vaccinations, such as DTtaP, polio, measles, Flu, and other required 
childhood vaccinations, the 2011 NIS – Teen obtained vaccination coverage rates for older 
children (41). The 2011 NIS-Teen identified households containing one or more children who 
were 13-17 years of age (41). Interviews were conducted with household adults who were most 
knowledgeable about the children’s vaccination records (41). After the completion of the 
household portion, the 2011 NIS-Teen also contacted the children’s vaccination providers to 
request information on vaccinations from the children’s medical records (41).  The 2011 NIS-
Teen response rate for the telephone household survey was 57.2 %, and the percentage of 
children with adequate provider data was 61.5 % (42).  
The criteria for inclusion in this research study were (n=5,965):  
A. Being female,  
B. Between 13-17 years of age by the time of the interview in 2011,  
C. At least one HPV shot was received, and  
D. The first HPV shot was received between 9 -17 years of age.  
Although the HPV vaccine series had been approved for 9-26 year-old children and 




was limited to those females who received at least one HPV shot and the first HPV shot was 
received between the ages of 9 -17. 
ACIP recommends that the HPV vaccination series can be started beginning at 9 years of 
age, but has not issued a recommendation for children younger than 9 years of age (7, 8, 43, 44). 
Therefore, children who reported having received at least one shot of the HPV vaccine series 
when they were less than 9 years of age were excluded from our study. The 2011 NIS – Teen 
staff completed data collection around the time that the ACIP released their recommendation for 
males in December 2011 (10, 11, 12). Because the ACIP recommendation for males was 
released after 2011 NIS-Teen data collection occurred, males were excluded from our study. The 
final sample size for this study is 5,965. 
Human Subjects & Ethical Issues 
The 2011 NIS public-use data file was used for this secondary data analysis study. The 
2011 NIS – Teen staff have taken various steps to ensure that participants’ sensitive information 
and confidentiality were protected from the beginning to the end of the survey (42). The 2011 
NIS-Teen staff also received prior human subjects’ approval from the Office of Management and 
Budget before starting their survey study (42). 
During the data collection phase, the 2011 NIS-Teen staff sent advance notification 
letters, provided an overview of the study, and obtained informed oral consent from the 
participants. These steps were taken in order to protect participants’ confidentiality and ensure 
them that their participation was entirely voluntary (42). Once participants were identified as 
having the most knowledge in the household in regards to the eligible children’s vaccine history, 




interview, the 2011 NIS-Teen interviewers asked the participants for permission to contact the 
children’s vaccination providers (42). 
Before the 2011 NIS – Teen public-use data files can be published on the CDC’s website, 
they had to go through an extensive process to protect participants’ privacy and data 
confidentiality (42). In accordance with the NCHS’s established standards for the release of all 
NCHS survey data, the 2011 NIS-Teen public-use data files were required to undergo a 
comprehensive review by the NCHS Disclosure Review Board (42). The 2011 NIS –Teen 
public-use data file webpage clearly indicates that the dataset can be used only for research 
purposes. Any violators of the privacy and confidentiality of the participants can be punished by 
law (45, 46). 
In December of 2013, the University of Maryland Institutional Review Board (IRB) 
reviewed this thesis’ "Human Subject Determination" Form and declared it “exempt.” Since the 
2011 NIS-Teen data was available to the public, the UMD IRB determined that this thesis meets 
at least one of the federal exempt categories criteria. Therefore, there is no requirement for 
annual review or expiration date listed on the final approval letter. 
Dependent Variable 
The outcome of interest was compliance regarding age at initiation of the HPV vaccine 
series. Based on the ACIP recommendation, those who received the first dose of HPV 
vaccination at or before 12 years of age were considered “on-time” initiators. Those who 
received the first dose of HPV vaccination after the age of 12 were considered “late” initiators. 
Based on the preliminary analyses of the dependent variables of this dataset, provider-
reported data were more complete than household-reported data. Provider data (n=7470), which 




considerably larger sample size, compared to the provider data (n=2172). Therefore, the 
provider-reported data from the 2011 NIS-Teen Survey were used for the data analysis (42).  
Independent Variables 
Race/Ethnicity. Race/ethnicity information was collected in the 2011 NIS-Teen with 
multiple categories. In compliance with the Office of Management and Budget’s (OMB) 
standards for federal statistics reporting and the classification of race/ethnicity in the United 
States, the 2011 NIS Teen collected data on race/ethnicity groups as follows: Hispanic, Non-
Hispanic White Only, Non-Hispanic Black Only, Alaska Native, Asian, Native Hawaiian/Pacific 
Islander, Other, Do not know, and Refused. The 2011 NIS – Teen had recoded race/ethnicity 
variables and categorized into Hispanic, Non-Hispanic White Only, Non-Hispanic Black Only, 
and Non-Hispanic Other and Multi-Racial (16, 42, 47).  
Socioeconomic Status. SES was determined by using the children’s “mother’s 
educational level” and “poverty status.” Mother’s education was sorted into four categories: 
college graduate, greater than 12 years but not completed college, 12 years, and less than 12 
years. 
Poverty status took into account the household income and number of people in the 
household. Based on the 2009 Census poverty thresholds, the 2011 NIS-Teen divided the 
poverty status into three categories (42). The categories were: 1) Those who are living at or 
above the federal poverty level and having a household income greater than $75,000 (Above 
poverty level, >&75K), 2) Those living at or above the federal poverty level and having a 
household income less than or equal to $75,000 (Above poverty level ≤$75K), and 3) Those 




Health insurance coverage. Information on health insurance coverage was gathered from 
the Health Insurance Module (HIM) in the NIS-Teen Survey. Response categories were included 
in the 2011 NIS-Teen survey as follows:  
a. Through employer or union (Private) 
b. Medicaid (Public) 
c. Child Health Insurance Plan-CHIP (Public) 
d. Medicaid or CHIP (Public) 
e. Indian Health Service (Other) 
f. Military Health Care, Tricare, Champus, or Champ-VA (Other)  
g. Other Health Insurance (Other) 
h. Uninsured (No insurance) 
 
Based on previous studies using NIS-Teen datasets to examine health insurance coverage 
variables and Census Bureau’s definitions of health insurance (16, 48, 56, 57), I re-categorized 
the health insurance coverage information as follows: Private, Public, Other, and None.  
Potential Confounders and Effect Modifiers 
From the existing literature, potential confounders for initiating HPV vaccine were family 
composition, previous vaccination history of other childhood vaccines, parent’s HPV vaccine-
related beliefs, attitudes, and intentions, having HPV-related knowledge, healthcare utilization, 
and having a healthcare provider as a source of information (20, 21). In this thesis, only potential 
confounding variables that were available in the NIS-Teen dataset were tested and controlled 
during the statistical analysis. These variables also met criteria for confounding (associated with 
both the exposure and the outcome while not a part of the causal pathway). From Figure 1, these 
variables include family composition (marital status, number of children in household under age 
18), healthcare utilization (number of primary care visits in past 12 months), and previous 
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A, Hepatitis B, Tdap, Meningococcal, MMR, Varicella zoster, Influenza) was available through 
the 2011 NIS-Teen, Hepatitis B vaccination history was chosen and used as a proxy for 
“previous vaccination history of childhood vaccines” (20, 21). Several peer-reviewed studies 
have found that vaccination history of hepatitis B to be the strongest predictor of HPV vaccine 
series initiation among females (49, 55). Hepatitis B vaccine protects against Hepatitis B viral 
infection, which is another type of sexually transmitted infection (STI) (50). Hepatitis B 
infection is prevalent among sexually active individuals and those who use drug needles (78). 
However, the source of infection is still unknown for 30% of those who currently have Hepatitis 
B infection today (78). Having Hepatitis B infection could lead to serious diseases, such as liver 
cancer and cirrhosis. Similar to the HPV vaccine’s numbers of dosage, Hepatitis B vaccine is 
given in a three-dose series over a 6-month period (50). The current Hepatitis B vaccination was 
used since in 1986 and in 2005, ACIP updated to its recommendation to include all children and 
adolescents ages < 19 years (50, 78). “Number of Hepatitis B vaccine” in this study was 
categorized into: 0, 1-2, 3, and 4 or more. 
Statistical Analysis 
For this thesis, the CDC public data file was downloaded and SAS version 9.3 was used. 
In the preliminary analyses, frequency distributions and univariate analyses were conducted to 
examine associations between on-time initiation of the first HPV shot and mother’s education, 
poverty level, race/ethnicity, and health insurance coverage. Descriptive statistics were used to 
provide a quantitative description of the study sample and examine the distribution of 
independent variables, dependent variables, and covariates. SES, race/ethnicity, health insurance 




Data were analyzed using SAS 9.3 survey procedures, and applying appropriate sampling 
weights because of the complex survey design. PROC SURVEYFREQ was used to examine the 
relationships between all variables and on-time vaccination. The Rao-Scott Chi-Square (χ2) Test 
was performed to examine significant differences between those who have initiated the HPV 
vaccine series “on-time” and those who initiated it “late.” Unadjusted logistic regression models 
were run for these variables separately. Then, multivariate logistic regression analysis was 
conducted to examine effects of independent variables on on-time initiation of HPV vaccine 
series while controlling for confounders. Adjusted odds ratios and 95% confidence intervals 
were calculated. 
Additionally, the complex sampling design was accounted for and addressed in the 
statistical analysis, as recommended in the 2011 NIS-Teen Data User’s Guide (42). The 2011 
NIS-Teen had already made an adjustment to the weights in order to account for differences 
among various groups. According to the 2011 NIS-Teen Data User’s Guide, children who had 
access to regular healthcare services were more likely to be captured in the provider data, 
compared to those who did not have regular healthcare services (42, 51). This group traditionally 
came from a wealthier population and had been over-represented in the provider data; therefore 
weights were developed and adjusted by the 2011 NIS-Teen in order to achieve an accurate 
representation of the survey’s target population. The weight variable “PROVWT_D” was 
therefore used to adjust for the dual sample frame of landline and cell phones, and take into 
account these differences in the population (42). 
To evaluate confounding and effect modifications, stratified analyses were performed for 
all potential confounders using PROC SURVEYLOGISTIC in SAS version 9.3. These variables 




healthcare utilization (number of primary care visits in past 12 months), and previous vaccination 
history of childhood vaccines (number of hepatitis B vaccine shots).  Additional criteria for 
assessing confounders used to test potential confounders included: 1) Confounding variable was 
associated with the exposure, 2) Confounding variable was associated with the outcome, and 3) 
Confounding variable was not part of the causal pathway between the exposure and the outcome. 
For example, one of the variables representing family composition was “mother’s marital status.” 
Mother’s marital status was categorized into: single or married. For example, mother’s marital 
status was stratified by race/ethnicity, poverty level, mother’s education, and health insurance 
coverage. To examine variables for confounding, the crude ORs was compared with the adjusted 
ORs. If the adjusted ORs were at least 10% different from the crude ORs, we determined the 
variable as a confounder. To examine variables for effect modification, we looked at the 
stratified ORs in the subgroup and determined if they are different from one another.  
To evaluate for multicollinearity, PROC REG and Variance Inflation Factor (VIF) were 
used in SAS 9.3. As the degree of VIF increases, the estimates from the logistic regression model 
become unstable. The result from the multicollinearity test indicated that none of our variables 
have VIF values greater than 10 (Appendix D). Therefore, multicollinearity is not a problem in 
this study.  
Lastly, sensitivity analyses were performed using the same SAS procedures but without 
12 and 13 age groups. Since the majority of the study sample received the first HPV shot at the 
ages of 12 and 13 (age 12 = 1,598 and age 13 = 1,321), we took out these age groups and ran the 
same procedures. We redefined those who received the first HPV shot between ages 9-11 year-
olds as “on-time” and ages 14-17 year-olds as “late.” The results of the sensitivity analyses were 




CHAPTER 5: RESULTS 
 
Descriptive statistics: Socio-demographic characteristics and distribution of age at 
initiation of HPV vaccines series  
Among 13-17 year old females who had received at least one HPV vaccine shot during 
2011 (n=5,965), 47.7% reported having received the first shot between 9-12 years of age or on-
time (Table 1).  
Table 2 presents socio-demographic and health care characteristics for 13-17 year old 
females who had received at least one HPV vaccine shot in 2011. On-time initiation ranged from 
49% for non-Hispanic Whites to 55% for Hispanics. Females who lived in households with more 
children were more likely to initiate their HPV vaccine series on-time. In addition, females who 
lived in households with higher incomes, and higher maternal education were less likely to 
initiate their HPV vaccine series on-time compared to females in lower socioeconomic status 
households. For example, 46.8% of females who lived in a household with an income over 
$75,000 had received their first HPV shot on-time compared to 54.3% of females living below 
the federal poverty level. Similarly, females with private health insurance coverage (32.4%) were 
the least likely to start their HPV vaccine series on-time than any other insurance group, 
including those without health insurance (43.7%). Females who had not received a Hepatitis B 
vaccine shot were also less likely to initiate their HPV vaccine series on-time (35.7%) compared 





Table 1: Weighted Percentages and Numbers of on-time and late initiators among 13-17 year-old 























































Total  2973  2886398  52.3% 
Total  5965  5517935  100% 
1Compliance of age at initiation of the HPV vaccine, defined as “on-time” vaccination based on the ACIP 
recommendation that the first of the three-dose HPV vaccine be given to girls by the ages of 11 or 12 years old. 
Children who received the first dose of HPV vaccination before or at the age of 12 are considered “on-time.”  
2 Children who received the first dose of HPV vaccination after the age of 12 are considered “late.” 
3Weight was used to adjust for the dual sample frame of landline and cellphone and take into account these 

























Table 2: Socio-demographic and health care characteristics of 13-17 year-old females who received at least one HPV vaccine shot in 


































































































































































































































































































































































































































* Weight was used to adjust for the dual sample frame of landline and cellphone and take into account these differences in the population. 
**In this study, “single” includes all those who are widowed, divorced, separated, and never married as well as those whose husbands are deceased. 
***Poverty status is based on the 2009 Census poverty thresholds to calculate income-to-poverty ratio. 





Univariate analyses of on-time HPV vaccine series among 13-17 year-old females 
Crude odds ratios (OR) were calculated to describe on-time initiators who have at least 
one HPV vaccine shot (Table 3). Additionally, 95% confidence intervals (CI) were used to 
estimate the precision of the OR. A wider CI showed low level of precision or confidence of the 
OR while a narrower CI showed greater precision of the OR. If the CI did not include 1, the OR 
was characterized as statistically significant. 
In the univariate analysis, several variables were significant predictors of having received 
on-time first HPV vaccine series (Table 3). Those with public health insurance coverage had 
1.826 (95% CI: 1.274, 2.619) odds of initiating on-time when compared to those with no health 
insurance coverage (Table 3). Females also had greater odds of initiating on-time if they received 
at least three Hepatitis B vaccine shots (3 Hepatitis B vaccine shots: 1.655, 95% CI: 1.035, 
2.647; 4 or more Hepatitis B vaccine shots: 2.343, 95% CI: 1.258, 4.363) (Table 3). 
Interestingly, females were less likely to initiate on-time if their households were above the 
poverty level compared to females whose households were below the poverty level (above 
poverty level >$75K: 0.746, 95% CI: 0.568, 0.98); above poverty level ≤$75K: 0.750, 95%CI: 
0.585, 0.961). Females with mothers who had more than 12 years of education, non-college 
graduate, had 0.664 (95% CI: 0.489, 0.903) odds of having on-time first HPV vaccine shot when 
compared to those whose mothers had less than 12 years of education (Table 3).  
Several factors previously found to be associated with HPV initiation in other studies 
(race/ethnicity, mother’s marital status, and private health insurance coverage) were not 
statistically significant in the analysis (Table 3). Race/ethnicity was not a significant predictor of 
on-time initiation. Hispanics had 1.011 (95% CI: 0.781, 1.310) odds to initiate on-time when 




1.289) odds of having an on-time first HPV vaccine shot when compared to non-Hispanic Whites 
(Table 3). Females with married mothers had 1.036 (95% CI: 0.846, 1.270) odds to initiate on-
time when compared to females with single mothers (Table 3). Although not significant, females 
with private health insurance coverage had greater odds of being on-time (OR: 1.379, 95%: 







































Table 3: Univariate analysis of on-time HPV vaccine initiation among 13-17 year-old females 

















































































* Weight was used to adjust for the dual sample frame of landline and cellphone and take into account these 
differences in the population. 
**In this study, “single” includes all those who are widowed, divorced, separated, and never married as well as those 
whose husbands are deceased. 
***Poverty status is based on the 2009 Census poverty thresholds to calculate income-to-poverty ratio. 
† Overall p-values for each variable indicate significant association between each variable and on-time initiation of 









Confounders for association between race/ethnicity, socioeconomic status, and health 
insurance status and on-time initiation of first HPV vaccine shot among 13-17 year-old 
females  
 
Hispanics with married mothers had 1.170 (95% CI: 0.841, 1.628) odds of having an on-
time first HPV shot than non-Hispanic Whites with married mothers (Table 4A). Hispanics with 
single mothers had 0.784 (95% CI: 0.510, 1.205) odds of having on-time first HPV shot than 
non-Hispanic Whites with single mothers (Table 4A). The crude odds ratio for Hispanics having 
higher odds than non-Hispanic Whites for on-time initiation of HPV vaccine series was 1.011 
(95% CI: 0.781, 1.310) in Table 3. Since there were at least 10% differences between the crude 
odds ratio and the adjusted odds ratio, we considered the variable of “mother’s marital status” as 
a confounder. The variable “marital status” was included in the multivariate logistic regression.  
Additionally, previous literature had noted that family composition was associated with 
higher prevalence rates of HPV initiation (20, 21). Children who do not receive HPV vaccination 
were associated to having married mothers (20, 21). Since literature indicated that there was an 
association between the outcome (on-time initiation of HPV vaccination) and the confounding 
variable (mother’s marital status), mother’s marital status met the second criteria for confounder.  
For the third criteria for confounding, marital status was not a part of the causal pathway 
between the exposure (marital status) and the outcome (on-time initiation of HPV vaccine 
series). For example, race/ethnicity did not cause someone’s marital status to be either single or 
married. Likewise, someone’s marital status did not cause either an on-time or late initiation of 
the first HPV vaccine shot. Therefore, marital status was not in the causal pathway between the 
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Table 4A: Stratified analysis of on-time initiation of first HPV vaccine by mother’s marital status and race/ethnicity, mother’s 















































































Table 4B: Stratified analysis of on-time initiation of first HPV vaccine by number of children under 18 in household, race/ethnicity, 


































































































Table 4C: Stratified analysis of on-time initiation of first HPV vaccine by number of primary care visits in the past 12 months, 










































































































































Table 4D: Stratified analysis of on-time initiation of first HPV vaccine by number of Hepatitis B shots, race/ethnicity, mother’s 










































































































Association between compliance with ACIP recommendations for age at initiation of the 
HPV vaccine series and socioeconomic status, race/ethnicity, and health insurance coverage 
 
Multivariate analysis was conducted to further evaluate the relationship between the 
exposure variables (mother’s education, poverty status, race/ethnicity, and health insurance 
coverage) and on-time initiation of HPV vaccine series while controlling for confounders (Table 
5). Variables were added to the multivariate logistic regression model to test for associations 
with the on-time initiation of first HPV shot and socioeconomic status, race/ethnicity, and health 
insurance coverage. All analyses incorporated the sample weight and survey design measures to 
ensure accurate interpretation of data.  
Socioeconomic status: On-time initiation of HPV vaccine series 
 
In the univariate analysis, those who were above poverty level, ≤$75K had 0.75 (95% CI: 
0.585, 0.961) odds of initiating on-time, compared to those below poverty level (Table 3). 
Females who were above poverty level, >$75K had 0.749 (95% CI: 0.575, 0.975) odds of 
initiating on-time, compared to those below poverty level (Table 3). After adjusting for marital 
status, number of children in the household under age 18, number of primary care visits in past 
12 months, and number of Hepatitis B vaccine shots in the multivariable analysis, females who 
were above poverty level, >$75K had 0.746 (95% CI: 0.568, 0.980) odds of initiating on-time, 
compared to those below poverty level (Table 5).  
Using the “mother’s education” variable, those whose mothers were college graduates 
had 0.833 (95% CI: 0.489, 0.903) odds to initiate on-time compared to those whose mothers 
have less than 12 years of education in the univariate analysis (Table 3). In the multivariate 
analysis (after adjusting for marital status, number of children in the household under age 18, 
number of primary care visits in past 12 months, and number of Hepatitis B vaccine shots), 




initiating on-time compared to those whose mothers had less than 12 years of education (Table 
5). 
 
Race/ethnicity: On-time initiation of HPV vaccine series 
Non-Hispanic Blacks and non-Hispanic Others and Multi-Racial were slightly less likely 
to initiate the HPV vaccine series on-time, compared to non-Hispanic Whites. In the univariate 
analysis, non-Hispanic Blacks had 0.971 (95% CI: 0.731, 1.289) odds of initiating on-time than 
non-Hispanic Whites (Table 3). Non-Hispanic Others and Multi-Racial had 0.811 (95% CI: 
0.569, 1.156) odds of initiating on-time compared to non-Hispanic Whites (Table 3). Hispanics 
had 1.011 (95% CI: 0.781, 1.310) odds of initiating on-time compared to non-Hispanic Whites 
(Table 3). 
In the multivariate analysis, Hispanics had 0.981 (95% CI: 0.753, 1.277) odds of 
initiating on-time HPV vaccination compared to non-Hispanic Whites (Table 5). Non-Hispanic 
Blacks had 0.969 (95% CI: 0.721, 1.302) while non-Hispanic Others and Multi-Racial had 0.828 
(95% CI: 0.589, 1.165) odds of initiating on-time HPV vaccination compared to non-Hispanic 
Whites (Table 5).  
Health insurance coverage: On-time initiation of HPV vaccine series 
 Public health insurance coverage appeared to have a significant association with on-time 
initiation of HPV vaccine series. In the univariate analysis, females with public health insurance 
coverage had 1.826 (95% CI: 1.274, 2.619) odds of initiating on-time than those with no health 
insurance (Table 3). Females who had private health insurance coverage were 1.379 (95% CI: 
0.978, 1.945) odds to initiate on-time, compared to those with no health insurance (Table 3). 
Those with health insurance coverage in the category of others had 0.970 (95% CI: 0.546, 1.781) 




Similar results were reported in the multivariate analysis. Females with public health 
insurance coverage had 1.825 (95% CI: 1.266, 2.631) odds of initiating on-time than females 
with no health insurance (Table 5). Females who had private health insurance coverage were 
1.355 (95% CI: 0.948, 1.937) odds to initiate on-time, compared to females with no health 
insurance (Table 5). Females with other health insurance coverage had 0.964 (95% CI: 0.524, 
1.774) odds of initiating on-time than females with no health insurance (Table 5).  
 
 
Table 5: Multivariate analysis of on-time HPV vaccine initiation among 13-17 year-old females 































































*Adjusted for 4 confounders, including marital status, number of children in the household under age 18,  













Sensitivity Analysis: Redefined “on-time” as 9-11 years olds and “late” as 14-17 years olds 
 
The majority of this study sample received their first HPV vaccine shot at the ages of 12 
and 13 (age group 12 = 1,598; age group 13 = 1,321), according to Table 1. Sensitivity analyses 
were performed to exclude the age groups 12 and 13 in the study sample. 
Similar results were found for the weighted percentages of on-time and late initiators in 
the sensitivity analysis compared to the original analysis. Among females who received at least 
one HPV vaccine shot during 2011 (n=3,046), 43.9% reported having received the first shot on-
time while 56.1% reported having received the first shot late (Table 6A).  
Table 6A: Sensitivity analysis for weighted percentages and numbers of on-time and late 
initiators among 13-17 year-old females who received at least one HPV vaccine shot in the 















































Total  1652  1603169  56.1% 
Total  3046  2856966  100% 
1Compliance of age at initiation of the HPV vaccine, defined as “on-time” vaccination based on the ACIP 
recommendation that the first of the three-dose HPV vaccine be given to girls by the ages of 11 or 12 years old. 
Children who received the first dose of HPV vaccination before or at the age of 12 are considered “on-time.”  
2 Children who received the first dose of HPV vaccination after the age of 12 are considered “late.” 
3Weight was used to adjust for the dual sample frame of landline and cellphone and take into account these 
differences in the population. 
 
Interesting and contrasting results were found for three variables in the sensitivity 
analysis when we excluded 12 and 13 year olds. Those who were above poverty level >$75K had 
1.344 (95% CI: 1.035, 1.745) odds of initiating on-time, compared to those below poverty level 




of initiating on-time compared to those whose mothers have less than 12 years of education in 
the univariate analysis (Table 6B). Private health insurance coverage appeared to have a 
significant association with on-time initiation of HPV vaccine series instead of public health 
insurance coverage in the original multivariate analysis. In the sensitivity analysis, females who 
had private health insurance coverage had 1.382 (95% CI: 1.024, 1.866) odds of initiating on-
time, compared to those with no health insurance (Table 6B).  
 
 
Table 6B: Sensitivity analysis for multivariate analysis of on-time HPV vaccine initiation among 
13-17 year-old females who received at least one HPV vaccine shot in the United States, 2011 































































*Adjusted for 4 confounders, including marital status, number of children in the household under age 18,  









CHAPTER 6: DISCUSSION 
 
 This study was one of the first studies focusing on timely initiation of the HPV 
vaccination series. Unlike much of the published research where the focus was mainly on 
initiation and completion of the HPV vaccination series, this study focused on compliance with 
ACIP recommendation regarding age at initiation.  
Consistent with previous studies, females who had health insurance coverage were more 
likely to initiate on-time than those who did not have health insurance coverage (20, 21). 
Possible reasons for this finding could be that those with public health insurance may be more 
likely to go to a community clinic, where there have been efforts to increase HPV vaccination 
(20, 21). Public health insurance coverage, such as Vaccines for Children Program (VFC), 
Immunization Grant Program (Section 317), Medicaid, and Children’s Health Insurance Program 
(CHIP) have helped to increase vaccine uptake for individuals who do not have health insurance 
(26, 27, 28, 29).  
Consistent with previous studies, we found that females whose mothers were college-
educated were significantly less likely to initiate on-time compared to those whose mothers had 
less than 12 years of education (63, 65, 66). We also found that females whose family income 
were above poverty level were significantly less likely to initiate on-time compared to those who 
live below poverty level. Although women with higher SES are more likely to use preventive 
services compared to their counterparts (75, 76, 77), several research studies have found that 
women with higher SES are also more likely to refuse or delay their children’s vaccination (62, 
63, 65, 66). Possible reasons for this finding could be that parents with higher education and 
income have heard, read, and/or saw negative aspects about the HPV vaccine in the news 




education may be more likely to obtain a lot of information through various media channels (62). 
Information regarding HPV vaccination through these channels may be incorrect. 
Misinformation could lead to confusion and even fear of obtaining HPV vaccination (62). Other 
reasons for delaying HPV vaccination are related to knowledge and belief of vaccine necessity 
(62). Some parents question the effectiveness of the HPV vaccine, believing that their children 
are not sexually active, or have concerns about lasting health problems (62). Because higher SES 
mothers tend to wait longer before allowing their children to initiate HPV vaccine, it could also 
provide an explanation why we see a difference in findings when the 12 and 13 year olds were 
dropped from the analysis. 
Our study did not find race/ethnicity to be significantly associated with timely initiation 
of HPV vaccine series (20, 21). Focused on factors associated with overall initiation of HPV 
vaccination, Kessels and Fishers’ studies found that Whites were more likely to initiate the HPV 
vaccine series compared to Hispanics and Blacks (20, 21). Kessels and Fishers’ findings are 
inconsistent with a more recent study, where they found that Hispanics and Blacks were more 
likely to initiate the HPV vaccine series. More recent studies also found that White parents are 
most likely to delay and refuse the HPV vaccine series for their children (62, 63, 65). The 
inconsistencies across studies’ results for the association between race/ethnicity and HPV 
vaccine initiation could explain the reason why we did not find a significant result for 
race/ethnicity in this study. High refusal of all childhood vaccines among White mothers who 
were college-educated and earned high incomes has been previously noted (63, 67). They may 
have lower perceived need for HPV vaccination due to higher access to regular cervical cancer 






Implications and Future Research 
The importance of HPV vaccination, especially on-time vaccination, deserves much 
attention by healthcare providers, parents, public health officials, policy makers, and all other 
HPV vaccination stakeholders. CDC estimates that only 30% of U.S. females received all three 
HPV doses by 13-15 years of age (13, 14). Of those who received at least one HPV vaccine shot, 
this study found that less than half (47.7%) complied with ACIP recommendation and received 
the first shot on-time (Table 1). To increase on-time HPV vaccination rates, evidence-based 
strategies should be adopted (74). For instance, healthcare providers should provide strong, clear, 
and consistent ACIP recommendation for HPV vaccine to parents (74). Policy makers can also 
address out-of-pocket expenses in the existing public insurance programs. These expenses could 
be associated with transportation fees or missed workday’s compensation (74). 
Future research is also needed to investigate the reason why we see contrasting results 
between analyses defining “on-time” initiators as 9-12 year-olds and in accordance to ACIP-
recommended age at initiation (1, 10, 11, 12) versus analyses that excluded children age 12 year-
olds. Multivariate analysis found that people who initiated on time are more likely to have public 
health insurance. People who live above poverty and whose mothers finished college are less 
likely to be on time. In contrast, sensitivity analysis excluding age 12 year-olds found higher SES 
and those with private health insurance are more likely to be on time, compared to their 
counterpart. Results vary based on how “on-time” initiation is defined.  
Further research is required to explore barriers associated with specific populations 
identified in this study as having lower on-time initiation. People who initiated on time are more 
likely to have public health insurance. People who live above poverty and whose mothers 
finished college are less likely to be on time. We need more research to focus in this area and dig 




Targeted interventions and policies can be developed to increase on-time initiators of HPV 
vaccination in the U.S. 
Strengths 
There were several strengths in using the NIS –Teen dataset. In the U.S., the 2011 NIS –
Teen dataset has been one of the best public health surveillance tools available for vaccination 
data. It provides us with a large, nationally representative sample size of children in the U.S. as 
well as information on the HPV vaccine uptake (42).  
Additionally, the 2011 NIS-Teen has a strong and comprehensive survey study design 
using random-digit-dial telephone survey for the households combined with the mail survey for 
the vaccination providers (42). Vaccination information from the providers is more likely to be 
up-to-date, complete, and reliable than household-reported information (53). The combination of 
the household-reported data and the provider-reported data provides a unique step to validate and 
ensure the accuracy of the HPV vaccination data.  
Limitations 
Several limitations of this study exist. First, this study’s analysis was limited by the 
variables included in the 2011 NIS-Teen Public Use Data File. The 2011 NIS-Teen only asked 
questions of mothers’ marital status and education but not fathers’. We were not able to exclude 
children who already have HPV infection at the time of the study. The 2011 NIS-Teen only 
asked parents and providers to provide dates when children received HPV vaccination, but no 
biological samples were collected to check for their HPV infection status. 
Second, the nature of the cross-sectional study design inhibited the ability to make direct 
causal inferences. Although direct causal relationships cannot be inferred from this cross-




independent variables (mother’s education, poverty status, race/ethnicity, health insurance status) 
and dependent variable (on-time initiation of HPV vaccination). 
Lastly, this study was limited to the most recent publically available data from the NIS –
Teen at the time of my proposal defense. NIS-Teen surveys were also conducted during 2012 
and 2013, but the 2012 NIS-Teen dataset was not available for public use until the end of 
December 2013. This limitation hindered our ability to assess more recent changes in HPV 
vaccination. With the implementation of the ACA, we are expecting rapid changes in health 
insurance coverage and many routine preventive services in the United States (27, 34, 35).  
Public Health Significance 
Timeliness for initiating the HPV vaccine series is essential in order to prevent cervical 
cancer (10, 47, 68, 69, 70). It is crucial to follow the ACIP recommendation regarding age at 
initiation of HPV vaccine series (HPV vaccination should be started at 11 or 12 years of age, but 
it can be started 9 years of age) to ensure that vaccinations are given at the correct timeline for 
optimal protection (47). Vaccinations are some of the most important public health tools 
available for preventing diseases (31, 32). Not only does vaccination protect children from 
developing potentially serious diseases, but they also protect the community by reducing the 
spread of infectious diseases (31, 32).  
Healthy People 2020 recognizes the importance of HPV vaccination through two 
objectives to increase HPV vaccination uptake (IID-11.4) and to reduce HPV infection (STI-9) 
(13, 14). To achieve these objectives, compliance with ACIP recommendation regarding age at 
initiation will help increase overall HPV vaccination rates, increase protection against HPV 
infection, and potentially decrease the risk of cervical cancer in adulthood (13, 14). Because the 




vaccination leaves children with a longer window of vulnerability to contract HPV infection (52, 




Appendix A: List of Variables used in this study, NIS-Teen, 2011 






































































































































































































































































































N/A  N/A  N/A  N/A 
 
 


















Appendix D: Test for Multicollinearity for Variables of Mother’s education, Poverty status, 








Appendix E: MPH Competencies address in thesis 
Competencies for MPH in 
Epidemiology 
Thesis Addressed in this Thesis 
1) Demonstrate the importance of 
epidemiology for informing 
scientific, ethical, economic, 
and political discussion of 
health issues.  
 
  
Epidemiologic analysis of variables associated with 
compliance at age at initiation in the HPV vaccine 
series and the public health significance of this study 
with suggestions for possible policy applications 
2) Assess a public health problem 
in terms of magnitude, person, 
time and place.  
 
  
Examine factors associated with on-time initiation of 
HPV vaccine series among 13-17 year-old females in 
the U.S. in 2011 
3) Distinguish the basic 




Statistical analysis and interpretation of results. 
4) Discriminate key sources of 




Use of 2011 NIS-Teen, strengths, and limitations 




Descriptive statistics displaying socio-demographic 
characteristics in the sample among 13-17 year-old 
females who received at least one HPV vaccine shot 
6) Identify the principles and 




Preventive services for cervical cancer, such as Pap 
smear test and HPV vaccine 
7) Evaluate strengths and 




Strengths and weaknesses in introduction and 
discussion sections 
8) Draw appropriate inferences 
from epidemiologic data.  
  Results and discussion sections 
9) Explain criteria for causality   Results and discussion sections (e.g. limitations) 




Univariate analysis, stratified analysis, and 
multivariate analysis to calculate odds ratios. 
Confidence interval is also included. 
11) Communicate epidemiologic 
information to lay and 
professional audiences.  
 
  
Written thesis report; oral thesis defense and final 
presentation of results and public health significance 
to audiences 
12) Compare basic ethical and legal 
principles pertaining to the 
collection, maintenance, use 
and dissemination of 
epidemiologic data.  
 
  
Discuss NIS-teen confidentiality and voluntary 
topics; obtain IRB approval before data analysis 
process. 
13) Design, analyze, and evaluate 
an epidemiologic study. 
  Design, conduct and write up thesis  
14) Design interventions to reduce 
prevalence of major public 
health problems.  
 
  
Discuss public health significance, future research 
and policy interventions to increase compliance to 
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